UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Annals of hematology, 2022-04, Vol.101 (4), p.755-762

2022

Volltextzugriff (PDF)

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level

Journal of clinical medicine, 2023-09, Vol.12 (18), p.5865

2023

Volltextzugriff (PDF)

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Blood, 2022-11, Vol.140 (Supplement 1), p.12349-12350

2022

Volltextzugriff (PDF)

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Blood, 2022-11, Vol.140 (Supplement 1), p.11981-11982

2022

Volltextzugriff (PDF)

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.118-124

2021

Volltextzugriff (PDF)

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Blood, 2019-11, Vol.134 (Supplement_1), p.5321-5321

2019

Volltextzugriff (PDF)

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.19-20

2020

Volltextzugriff (PDF)

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood, 2019-11, Vol.134 (Supplement_1), p.982-982

2019

Volltextzugriff (PDF)

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

The Lancet. Haematology, 2022-06, Vol.9 (6), p.e403-e414

2022

Volltextzugriff (PDF)

Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity

The American journal of medicine, 2004, Vol.117 (6), p.440-441

2004

Volltextzugriff (PDF)

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Blood, 2016-12, Vol.128 (22), p.3008-3008

2016

Volltextzugriff (PDF)

Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

American journal of hematology, 2013-02, Vol.88 (2), p.130-134

2013

Volltextzugriff (PDF)

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Blood, 2019-11, Vol.134 (Supplement_1), p.1766-1766

2019

Volltextzugriff (PDF)

Severe Osteomyelitis of the Jaws in Long Term Survivorsmultiple Myeloma Patients Treated with Biphosphonates.A New Clinical Entity

Blood, 2004-11, Vol.104 (11), p.4900-4900

2004

Volltextzugriff (PDF)

Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15 (6), p.e95-e99

2015

Volltextzugriff (PDF)

Influence of Phlebotomies on Arterial Hemodynamic Parameters in Polycythemia Vera Patients

Blood, 2005-11, Vol.106 (11), p.4945-4945

2005

Volltextzugriff (PDF)

Influence of Hemotransfusion on the Arterial Compliance in the Patients with Chronic Anemia

Blood, 2005-11, Vol.106 (11), p.4173-4173

2005

Volltextzugriff (PDF)

Osteomyelitis of the Jaw in Multiple Myeloma Patients as a Complication of the Treatment with Biphosphonates

Blood, 2005-11, Vol.106 (11), p.5141-5141

2005

Volltextzugriff (PDF)

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Acta haematologica, 2006-01, Vol.115 (1-2), p.113-116

2006

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

ThemaSurvival

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Severe Osteomyelitis of the Jaws in Long Term Survivorsmultiple Myeloma Patients Treated with Biphosphonates.A New Clinical Entity

Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

Influence of Phlebotomies on Arterial Hemodynamic Parameters in Polycythemia Vera Patients

Influence of Hemotransfusion on the Arterial Compliance in the Patients with Chronic Anemia

Osteomyelitis of the Jaw in Multiple Myeloma Patients as a Complication of the Treatment with Biphosphonates

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Aktive Filter

Suchergebnisse filtern